The paper argues that the Institute of Medicine (IOM) made a statistical mistake when deriving the Recommended Dietary Allowance (RDA) for vitamin D, so 600 IU/day does not, in fact, ensure adequate vitamin D status for 97.5% of individuals.[1]

Core claim

The IOM intended the vitamin D RDA to be the intake that gives at least 50 nmol/L of serum 25(OH)D in 97.5% of healthy people, and set this at 600 IU/day based on pooled supplementation studies at high latitudes in winter. The authors show that the IOM actually used a prediction interval for study means, not for individuals, so the 600 IU figure only predicts that 97.5% of future study averages exceed about 50 nmol/L, not that 97.5% of people do.[1]

Corrected statistical interpretation

Using the eight trials that reported both mean and standard deviation, the authors reconstructed the lower tail (about the 2.5th percentile) of individual 25(OH)D values at each dose by subtracting two standard deviations from the mean. Regressing these reconstructed 2.5th percentiles on vitamin D intake showed that 600 IU/day would give 97.5% of individuals a level above only about 26.8 nmol/L, not 50 nmol/L.[1]

Implications for required intake

Extrapolating the same regression, the intake needed so that 97.5% of individuals reach at least 50 nmol/L is estimated at roughly 8900 IU/day, well above both the current RDA (600 IU) and the IOM’s tolerable upper intake level of 4000 IU/day. The authors stress that this estimate lies outside the range of doses actually studied, so it should be interpreted cautiously, but it clearly implies the true requirement is far above 600 IU/day.[1]

Public health impact

The authors point to Canadian data, where background diet provides about 232 IU/day, showing that even with supplements of 400 IU or more (total ≥632 IU/day), 10–15% of adults still have 25(OH)D below 50 nmol/L. If the RDA were correctly set for 97.5% coverage, fewer than 2.5% should fall below this threshold, so these observations empirically support the claim that the current RDA is too low.[1]

Recommendation

Because the misinterpretation leads to underestimation of vitamin D needs, the authors conclude that the vitamin D RDA should be revisited so that public health guidance and clinical decisions are based on requirements of individuals rather than study averages. They argue that without such correction, goals related to bone health and prevention of vitamin D–related disease cannot be reliably met.[1]

1

https://pmc.ncbi.nlm.nih.gov/articles/PMC4210929/

The reanalysis paper suggests that, to get about 97.5% of people to at least 20 ng/mL (50 nmol/L), an intake around 8,900 IU/day would be needed, which is far above current official recommendations. However, major medical bodies still advise much lower routine doses and treat such high intakes as above the usual safe upper limit.[1][2][3][4][5]

What the reanalysis suggests

• Using the same data the Institute of Medicine used, the statisticians estimated that about 8,895 IU/day would be required so that 97.5% of individuals reach at least 50 nmol/L (20 ng/mL).[3][1]
• This is roughly 10–15 times higher than the current RDA of 600 IU/day for most adults, which they argue is the result of a statistical miscalculation.[4][1]

What official bodies recommend

• The Institute of Medicine (now the National Academies) RDA is 600 IU/day for adults up to 70 and 800 IU/day for those over 70, with a tolerable upper intake level of 4,000 IU/day.[4]
• The Endocrine Society suggests that many adults may need 1,500–2,000 IU/day to keep blood levels consistently above about 30 ng/mL (75 nmol/L), which they consider a preferable minimum.[2][5]

Practical takeaways

• The “8,900 IU” figure is an argument that the true RDA (to cover almost everyone) is much higher than current guidelines, not a blanket dose recommendation for individuals.[1][3]
• In practice, most mainstream advice lands around 1,000–2,000 IU/day as a generally safe supplement dose for adults, with higher doses reserved for people monitored by a clinician who is checking blood 25‑OH vitamin D levels and other risk factors.[6][5]

1
2
3
4
5
6
7
8
9
10
11

• 00:01 🦠 Vitamin D supplementation reduces the incidence of COVID-19.

  • Vitamin D supplementation has a protective effect against COVID-19 in randomized controlled trials.
  • Odds ratio of 0.43 indicates a 60% protective effect.
  • Healthcare workers experienced an 80% reduction in risk with vitamin D supplementation.

• 02:47 📊 Meta-analysis confirms significant association between vitamin D and COVID-19 protection.

  • Meta-analysis concludes a definitive and significant link between vitamin D and reduced COVID-19 incidence.
  • Study titled "Vitamin D Supplementation and the Risk for COVID-19 Infection: A Systematic Review and Meta-analysis" published in February 2024.
  • Consensus on the protective role of vitamin D in both COVID-19 incidence and ICU admissions.

• 03:02 📚 Vitamin D's crucial roles in health and immunity.

  • Vitamin D plays crucial roles in bone health, muscle function, and immune response.
  • Optimizing vitamin D levels may protect against a range of cancers.
  • Strong scientific evidence supports the importance of vitamin D in immune system modulation.

• 04:25 🧪 Understanding the role of vitamin D in immune response.

  • Systematic reviews and meta-analysis highlight vitamin D's impact on the immune response to viruses.
  • Vitamin D supplementation shows a protective role in COVID-19 incidence among a large population.
  • Further research is needed to determine vitamin D's impact on mortality rates.

• 06:28 💡 Mechanisms of vitamin D action in the body.

  • Vitamin D mediates its effects through vitamin D receptors (VDRs) in nucleated cells.
  • VDR activation by vitamin D regulates gene expression crucial for immunity and metabolism.
  • Approximately 3% of the human genome is under the control of activated vitamin D, emphasizing its broad impact on health.

• 08:01 🔬 Vitamin D's role in immune function and disease prevention.

  • Vitamin D contributes to the synthesis of immune proteins and enhances phagocytic activity.
  • Modulates the immune system response by regulating inflammatory cascades, reducing the risk of cytokine storms.
  • Optimizing vitamin D levels may help mitigate pathological reactions to infections.

• 09:34 💊 Immediate benefits of activated vitamin D (calcidiol) supplementation.

  • Activated vitamin D (calcidiol) offers immediate benefits compared to standard vitamin D supplementation.
  • Calcidiol activates within a couple of hours, potentially aiding in combating acute infections.
  • Consideration of calcidiol supplementation for individuals with low vitamin D levels during acute infections is suggested.

• 11:41 ✅ Advocating for vitamin D supplementation in healthcare.

  • Research supports the efficacy of vitamin D in reducing COVID-19 incidence and severity.
  • Urgent consideration for vitamin D supplementation in acute infection cases is recommended.
  • The accessibility and affordability of vitamin D make it a viable option for public health intervention.

You need Magnesium w/ Vitamin D....and vitamin K?

Vitamin D3 supplementation in the range of 4000 to 10,000 units (100 to 250 µg) needed to generate an optimal 40–60 ng/mL (100 to 150 nmol/L)

has been shown to be completely safe when combined with approximately 200 µg vitamin K2

Background: COVID-19 is a major pandemic that has killed more than 196,000 people. The COVID-19 disease course is strikingly divergent. Approximately 80-85% of patients experience mild or no symptoms, while the remainder develop severe disease. The mechanisms underlying these divergent outcomes are unclear. Emerging health disparities data regarding African American and homeless populations suggest that vitamin D insufficiency (VDI) may be an underlying driver of COVID-19 severity. To better define the VDI-COVID-19 link, we determined the prevalence of VDI among our COVID-19 intensive care unit (ICU) patients. Methods: In an Institutional Review Board approved study performed at a single, tertiary care academic medical center, the medical records of COVID-19 patients were retrospectively reviewed. Subjects were included for whom serum 25-hydroxycholecalcifoerol (25OHD) levels were determined. COVID-19-relevant data were compiled and analyzed. We determined the frequency of VDI among COVID-19 patients to evaluate the likelihood of a VDI-COVID-19 relationship. Results: Twenty COVID-19 patients with serum 25OHD levels were identified; 65.0% required ICU admission.The VDI prevalence in ICU patients was 84.6%, vs. 57.1% in floor patients. Strikingly, 100% of ICU patients less than 75 years old had VDI. Coagulopathy was present in 62.5% of ICU COVID-19 patients, and 92.3% were lymphocytopenic. Conclusions: VDI is highly prevalent in severe COVID-19 patients. VDI and severe COVID-19 share numerous associations including hypertension, obesity, male sex, advanced age, concentration in northern climates, coagulopathy, and immune dysfunction. Thus, we suggest that prospective, randomized controlled studies of VDI in COVID-19 patients are warranted.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the following sources: 1) Louisiana State University Health Sciences Center; 2) 1R01HL118557-01A1, NIHLBI, NIH; 3) ASH Bridge Funding; 4) Texas A&M University System; 5) National Institutes of Health grant AI40165.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

The authors confirm that the data supporting the findings of this study are available within the article.